350 related articles for article (PubMed ID: 32892355)
41. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
[TBL] [Abstract][Full Text] [Related]
42. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.
Clinton LK; Blurton-Jones M; Myczek K; Trojanowski JQ; LaFerla FM
J Neurosci; 2010 May; 30(21):7281-9. PubMed ID: 20505094
[TBL] [Abstract][Full Text] [Related]
43. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study.
Lace G; Savva GM; Forster G; de Silva R; Brayne C; Matthews FE; Barclay JJ; Dakin L; Ince PG; Wharton SB;
Brain; 2009 May; 132(Pt 5):1324-34. PubMed ID: 19321462
[TBL] [Abstract][Full Text] [Related]
44. Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.
Chai YL; Chong JR; Weng J; Howlett D; Halsey A; Lee JH; Attems J; Aarsland D; Francis PT; Chen CP; Lai MKP
Brain Pathol; 2019 Jan; 29(1):63-74. PubMed ID: 30051532
[TBL] [Abstract][Full Text] [Related]
45. Dysexecutive Alzheimer's Disease with Lewy Body Disease Co-Pathology.
Coburn RP; Botha H; Graff-Radford J; Reichard RR; Jones DT; Ramanan VK
Curr Alzheimer Res; 2022; 19(4):330-333. PubMed ID: 35260054
[TBL] [Abstract][Full Text] [Related]
46. In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.
Hanko V; Apple AC; Alpert KI; Warren KN; Schneider JA; Arfanakis K; Bennett DA; Wang L
Neurobiol Aging; 2019 Feb; 74():171-181. PubMed ID: 30453234
[TBL] [Abstract][Full Text] [Related]
47. Coexisting pathologies in the brain: influence of vascular disease and Parkinson's disease on Alzheimer's pathology in the hippocampus.
Smith MZ; Nagy Z; Barnetson L; King EM; Esiri MM
Acta Neuropathol; 2000 Jul; 100(1):87-94. PubMed ID: 10912925
[TBL] [Abstract][Full Text] [Related]
48. Memory performance is related to amyloid and tau pathology in the hippocampus.
Reitz C; Honig L; Vonsattel JP; Tang MX; Mayeux R
J Neurol Neurosurg Psychiatry; 2009 Jul; 80(7):715-21. PubMed ID: 19258354
[TBL] [Abstract][Full Text] [Related]
49. Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes.
Müller-Ehrenberg L; Riphagen JM; Verhey FRJ; Sack AT; Jacobs HIL;
J Alzheimers Dis; 2018; 66(2):811-823. PubMed ID: 30320590
[TBL] [Abstract][Full Text] [Related]
50. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
[TBL] [Abstract][Full Text] [Related]
51. Entorhinal-Hippocampal Circuit Integrity Is Related to Mnemonic Discrimination and Amyloid-β Pathology in Older Adults.
Adams JN; Kim S; Rizvi B; Sathishkumar M; Taylor L; Harris AL; Mikhail A; Keator DB; McMillan L; Yassa MA
J Neurosci; 2022 Nov; 42(46):8742-8753. PubMed ID: 36302636
[TBL] [Abstract][Full Text] [Related]
52. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.
Coughlin DG; Phillips JS; Roll E; Peterson C; Lobrovich R; Rascovsky K; Ungrady M; Wolk DA; Das S; Weintraub D; Lee EB; Trojanowski JQ; Shaw LM; Vaishnavi S; Siderowf A; Nasrallah IM; Irwin DJ; McMillan CT;
Neurobiol Aging; 2020 Dec; 96():137-147. PubMed ID: 33002767
[TBL] [Abstract][Full Text] [Related]
53. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.
Shim KH; Kang MJ; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2022 Dec; 14(1):201. PubMed ID: 36587215
[TBL] [Abstract][Full Text] [Related]
54. Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease.
Cherry JD; Esnault CD; Baucom ZH; Tripodis Y; Huber BR; Alvarez VE; Stein TD; Dickson DW; McKee AC
Acta Neuropathol Commun; 2021 May; 9(1):86. PubMed ID: 33980303
[TBL] [Abstract][Full Text] [Related]
55. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease.
Uemura MT; Robinson JL; Cousins KAQ; Tropea TF; Kargilis DC; McBride JD; Suh E; Xie SX; Xu Y; Porta S; Uemura N; Van Deerlin VM; Wolk DA; Irwin DJ; Brunden KR; Lee VM; Lee EB; Trojanowski JQ
Acta Neuropathol; 2022 Jan; 143(1):15-31. PubMed ID: 34854996
[TBL] [Abstract][Full Text] [Related]
56. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
57. Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease.
Salmon DP; Smirnov DS; Coughlin DG; Hamilton JM; Landy KM; Filoteo JV; Hiniker A; Hansen LA; Galasko D
Neurology; 2022 Nov; 99(18):e2034-e2043. PubMed ID: 36028327
[TBL] [Abstract][Full Text] [Related]
58. Different patterns of hippocampal subfield pathology in Lewy body disease and Alzheimer's disease.
Jellinger KA
Neuropathol Appl Neurobiol; 2021 Aug; 47(5):705-706. PubMed ID: 33471382
[No Abstract] [Full Text] [Related]
59. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
Schaeffer MJ; Callahan BL;
J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
[TBL] [Abstract][Full Text] [Related]
60. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
